Emmes

Emmes is a long-established, privately-held clinical research organization (CRO) with a strong focus on complex, mission-critical research for a diverse client base including top biopharma companies and government agencies. The company differentiates itself by branding as the industry's first 'Native Digital and AI Specialty CRO,' integrating technology and AI across patient engagement, data management, and biostatistics to improve trial efficiency and outcomes. With deep expertise in therapeutic areas like Vaccines, Ophthalmology, Rare Disease, and Cell & Gene Therapy, Emmes leverages a high client retention rate and extensive site network to maintain its position as a trusted partner in advancing human health.

Positioned as a 'Native Digital and AI Specialty CRO.' Integrates technology and AI end-to-end across clinical functions including patient/site engagement, data management (with workflow automation and automated queries), and biostatistics/bioinformatics (with AI-assisted analysis and reporting). Aims to retool operations through monitoring, automated builds, and AI to improve speed, efficiency, and quality.

Emmes competes in the global full-service CRO market against large public players like IQVIA, ICON, Parexel, and PPD, as well as numerous mid-sized and specialty CROs. Its differentiation strategy hinges on being a 'Native Digital and AI Specialty CRO' and deep therapeutic expertise in complex areas, rather than competing solely on scale. It must continually innovate to maintain an edge as all major competitors are also investing heavily in digital and data capabilities.